Submit Deal

Announced

27 Oct 2021

Completed

27 Oct 2021

Koch Disruptive Technologies led a $215m Series B round in Immunai.

Synopsis

Koch Disruptive Technologies led a $215m Series B round in Immunai, a New York-based biotech company, with participation from Talos VC, 8VC, Alexandria Venture Investments, Piedmont and ICON. The new capital will be used to expand Immunai’s “drug actuary” platform for target validation and evaluation.

Principals

target

IMMUNAI

bidder

Piedmont Venture Capital

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (3)

luis voloch

CTO at IMMUNAI

Manager

target

Deal

£ 156 M

Total Value

kayla abbassi

Vice President at IMMUNAI

Manager

target

Deal

£ 156 M

Total Value

noam solomon

CEO at IMMUNAI

Manager

target

Deal

£ 156 M

Total Value

Bidder Team (5)

sean talbott

Managing Director at PIEDMONT VENTURE CAPITAL

Manager

bidder

Deal

£ 156 M

Total Value

john t. dimos

Principal at ALEXANDRIA VENTURE INVESTMENTS

Investor

bidder

Deals

£ 362 M

Total Value

eli groner

Managing Director at KOCH DISRUPTIVE TECHNOLOGIES

Investor

bidder

Deal

£ 156 M

Total Value

joe lonsdale

Managing Partner at 8VC

Investor

bidder

Deals

£ 1.37 B

Total Value

joe horowitz

Managing General Partner at ICON VENTURES

Investor

bidder

Deals

£ 1.38 B

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy